Program
ostarine
Also written as “GTx-024”, “Enobosarm” and “GTx-024 9mg”.
Its studies are mostly in Breast Neoplasms · Urinary Incontinence, Stress · Muscular Atrophy · Obesity · Triple Negative Breast Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GTx | 110 open or running | phase 3since May 12, 2011 | Apr 30, 2007 | none ahead |
| Veru | 31 open or running | phase 3since Apr 27, 2021 | Apr 27, 2021 | Oct 2027phase 2 · NCT07446998 |
| Havah Therapeutics Pty | 10 open or running | phase 1since Aug 14, 2017 | Aug 14, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2007First study: phase 2 study in CachexiaNew to GTxGTx · NCT00467844 · 159 enrolled · United States, Canada
- May 12, 20112 phase 3 studies in Muscular AtrophyGTx · NCT01355497, NCT01355484
- Jun 7, 2012Phase 2 study in Breast NeoplasmsGTx · NCT01616758 · 22 enrolled · United States
- Feb 10, 2015Phase 2 study in Triple Negative Breast NeoplasmsGTx · NCT02368691 · 32 enrolled · United States
- Jun 2, 2015Phase 2 study in ER+ and AR+ Breast CancerGTx · NCT02463032 · 136 enrolled · United States
- Jan 13, 2016Phase 2 study in Urinary Incontinence, StressGTx · NCT02658448 · 19 enrolled · United States
- Apr 18, 2016Phase 2 study in ER+ and AR+ Breast CancerGTx · NCT02746328 · United States
- Aug 2, 2017Phase 2 study in Urinary Incontinence, StressGTx · NCT03241342 · 491 enrolled · United States
- Aug 14, 2017Havah Therapeutics Pty's first study: phase 1 study in Mammographic DensityNew to Havah Therapeutics PtyHavah Therapeutics Pty · NCT03264651 · 9 enrolled · Australia
- Apr 16, 2018Phase 2 study in Urinary Incontinence, StressGTx · NCT03508648 · United States
- May 30, 2018Phase 2 study in Urinary Incontinence, StressGTx · NCT03566290 · United States
- Apr 27, 2021Veru's first study: phase 3 study in Breast NeoplasmsNew to VeruVeru · NCT04869943 · 52 enrolled · United States, Poland, Spain and more
- Feb 20, 2024Phase 2 study in Muscular AtrophyVeru · NCT06282458 · 168 enrolled · United States
- Feb 25, 2026Phase 2 study in ObesityVeru · NCT07446998 · 239 enrolled · United States
Ahead
- Oct 2027Primary completion: phase 2 study in ObesityVeru · NCT07446998
TargetBeta
“Androgen Receptor modulator”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07446998Obesity · United States | 2 | Active, not recruiting | Veru | Oct 2027 | 239 |
| NCT06282458Muscular Atrophy · United States | 2 | Completed | Veru | Apr 11, 2025 | 168 |
| NCT04869943Breast Neoplasms · United States, Poland, Spain and more | 3 | Terminated | Veru | Jan 9, 2024 | 52 |
| NCT03566290Urinary Incontinence, Stress · United States | 2 | Withdrawn | GTx | Sep 21, 2018 | 0 |
| NCT03508648Urinary Incontinence, Stress · United States | 2 | Withdrawn | GTx | Sep 21, 2018 | 0 |
| NCT03264651Mammographic Density · Australia | 1 | Completed | Havah Therapeutics Pty | Mar 21, 2018 | 9 |
| NCT03241342Urinary Incontinence, Stress · United States | 2 | Completed | GTx | Sep 21, 2018 | 491 |
| NCT02746328ER+ and AR+ Breast Cancer · United States | 2 | Withdrawn | GTx | Feb 2018 | 0 |
| NCT02658448Urinary Incontinence, Stress · United States | 2 | Completed | GTx | Jun 2018 | 19 |
| NCT02463032ER+ and AR+ Breast Cancer · United States | 2 | Completed | GTx | Mar 2019 | 136 |
| NCT02368691Triple Negative Breast Neoplasms · United States | 2 | Terminated | GTx | Sep 22, 2017 | 32 |
| NCT01616758Breast Neoplasms · United States | 2 | Terminated | GTx | Jun 2014 | 22 |
| NCT01355497Muscular Atrophy · United States | 3 | Completed | GTx | May 2013 | 330 |
| NCT01355484Muscular Atrophy · United States | 3 | Completed | GTx | May 2013 | 321 |
| NCT00467844Cachexia · United States, Canada | 2 | Completed | GTx | Sep 2008 | 159 |
How it is read
Names in the registry
- “GTx-024”, 9 entries
- “Enobosarm”, 3 entries
- “GTx-024 9mg”, 1 entry
- “GTx-024 9 or 18 mg”, 1 entry
- “GTx 024”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 4 studies
- Urinary Incontinence, Stress, 4 studies
- Muscular Atrophy, 3 studies
- Obesity, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.